Press Release: aap signs several agreements with US distributors - Kick off for LOQTEQ(R) sales in Q3/2015

aap Implantate AG / aap signs several agreements with US distributors - Kick off for LOQTEQ(R) sales in Q3/2015 . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

aap Implantate AG (XETRA: AAQ.DE) has reached a further, decisive milestone in developing the strategically important US market. The company has signed the first eight contracts for the distribution of its LOQTEQ(R) products with non-stocking distributors. On the basis of these agreements these distributors will cover different regions in the federal states California, Texas, Ohio, Tennessee, Oklahoma and Utah. The company anticipates initial sales in the US market in the third quarter of the current financial year.

aap Implantate AG is banking in the United States on a hybrid distribution model. The company plans to sell its LOQTEQ(R) products locally via both stocking (distributor buys the products) and non-stocking distributors (distributor is supplied with the products and pays after usage). Here, it should be noted that most of the sales in the USA are handled via non-stocking distributors.

In recent months the company has successfully built up the necessary infrastructure for the distribution of its LOQTEQ(R) products in the United States. The first move was to set up a US distribution company, aap

Implants Inc., and all distribution activities are managed by a new experienced Sales Director. In addition, an agreement was signed with a logistics service provider who will be responsible for the logistics of products to distributors and hospitals.

With the contracts signed, sales of LOQTEQ(R) products in the US now get kicked off. The next steps include the provision of necessary inventories and the execution of various product training courses and sessions for the distributors' sales employees. Furthermore, aap

Implantate AG will be stepping up significantly its presence at the leading relevant trade shows and events in the United States.

In order to reach an optimal geographic coverage as well as to extend the presence in this strategically important market, aap

Implantate AG will further push the acquisition of distributors in the coming months and intensify distribution activities.

About aap Implantate AG

aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma and biomaterials products for orthopedics. The trauma portfolio includes besides the innovative anatomical plating system LOQTEQ(R) a wide range of cannulated screws as well as standard plates and screws. In the biomaterials business the company is specialized on bone cements and mixing systems. In German-speaking countries aap Implantate AG directly sells its trauma products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 60 countries at the international level. In the biomaterials business sales are handled via OEM and private label cooperations with several selected international orthopedic and trauma companies. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement

This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

For inquiries please contact: aap Implantate AG, Fabian Franke, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany

Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: f.franke@aap.de

This announcement is distributed by Nasdaq OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: aap Implantate AG via Globenewswire

HUG#1927577

--- End of Message ---

aap Implantate AG

Lorenzweg 5 Berlin Germany

WKN: 506660;ISIN: DE0005066609;

Listed: Freiverkehr in Börse Stuttgart,

Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,

Freiverkehr in Börse Berlin,

Freiverkehr in Börse Düsseldorf,

Freiverkehr in Bayerische Börse München,

Freiverkehr in Niedersächsische Börse zu Hannover,

Prime Standard in Frankfurter Wertpapierbörse,

Regulierter Markt in Frankfurter Wertpapierbörse;

http://www.aap.de (END) Dow Jones Newswires

   June 10, 2015 07:07 ET (11:07 GMT)- - 07 07 AM EDT 06-10-15